Arizona is headed toward funding the first controlled clinical trials for whole mushroom psilocybin, or “magic mushrooms,” to treat an array of health issues, including post-traumatic stress disorder, anxiety and depression.
The state’s nearly $18 billion 2024 budget contains a provision providing $5 million for whole mushroom psilocybin trials. The money is the culmination of the efforts of Dr. Sue Sisely, an internal medicine physician and principal investigator at Scottsdale Research Institute, which conducts nonprofit drug development research on psychedelics, along with a bipartisan group of state legislators.
“We’re thrilled that the research on natural mushrooms will finally be able to move forward, so this is a big achievement that finally we’re going to get objective data,” Sisely told the Arizona Mirror. “This will give us reliable insight into how these mushrooms might help or harm people. We need to learn more about how this works.”